Bharat [BIBCL] vs Zota Health Care [ZOTA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bharat Immunologicals & Biologicals Corporation Limited wins in 9 metrics, Zota Health Care Limited wins in 8 metrics, with 0 ties. Bharat Immunologicals & Biologicals Corporation Limited appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bharat Immunologicals & Biologicals Corporation Limited | Zota Health Care Limited | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.59 | -62.53 | Bharat Immunologicals & Biologicals Corporation Limited |
| Price-to-Book Ratio | 0.97 | 12.61 | Bharat Immunologicals & Biologicals Corporation Limited |
| Debt-to-Equity Ratio | 94.48 | 56.90 | Zota Health Care Limited |
| PEG Ratio | -0.08 | -0.59 | Bharat Immunologicals & Biologicals Corporation Limited |
| EV/EBITDA | -7.13 | -126.59 | Bharat Immunologicals & Biologicals Corporation Limited |
| Profit Margin (TTM) | -241.59% | -15.37% | Zota Health Care Limited |
| Operating Margin (TTM) | -2,888.44% | -15.88% | Zota Health Care Limited |
| Return on Equity | -21.00% | -24.83% | Bharat Immunologicals & Biologicals Corporation Limited |
| Return on Assets (TTM) | -6.28% | -12.84% | Bharat Immunologicals & Biologicals Corporation Limited |
| Free Cash Flow (TTM) | $108.92M | $-959.42M | Bharat Immunologicals & Biologicals Corporation Limited |
| Dividend Yield | N/A | 0.07% | N/A |
| 1-Year Return | -32.86% | 27.17% | Zota Health Care Limited |
| Price-to-Sales Ratio (TTM) | 9.97 | 8.34 | Zota Health Care Limited |
| Enterprise Value | $1.42B | $45.66B | Zota Health Care Limited |
| EV/Revenue Ratio | 18.52 | 9.66 | Zota Health Care Limited |
| Gross Profit Margin (TTM) | N/A | 60.28% | N/A |
| Revenue per Share (TTM) | $2 | $157 | Zota Health Care Limited |
| Earnings per Share (Diluted) | $-3.59 | $-23.94 | Bharat Immunologicals & Biologicals Corporation Limited |
| Beta (Stock Volatility) | 0.34 | 0.36 | Bharat Immunologicals & Biologicals Corporation Limited |
Bharat Immunologicals & Biologicals Corporation Limited vs Zota Health Care Limited Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bharat Immunologicals & Biologicals Corporation Limited | 0.71% | -1.61% | -1.38% | 5.28% | -9.50% | -14.68% |
| Zota Health Care Limited | 1.75% | 3.68% | 3.22% | 14.06% | -26.10% | -17.99% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bharat Immunologicals & Biologicals Corporation Limited | -32.86% | -26.70% | -80.09% | -12.27% | 29.14% | 57.16% |
| Zota Health Care Limited | 27.17% | 243.00% | 632.12% | 1,248.00% | 1,248.00% | 1,248.00% |
Performance & Financial Health Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs Zota Health Care Limited
| Metric | BIBCL | ZOTA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹762.99M | ₹39.41B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 35,100 | 56,411 |
| 90 Day Avg. Volume | 35,515 | 53,265 |
| Last Close | ₹17.14 | ₹1,246.70 |
| 52 Week Range | ₹14.10 - ₹25.65 | ₹917.20 - ₹1,740.00 |
| % from 52W High | -33.18% | -28.35% |
| All-Time High | ₹94.50 (Jun 14, 2021) | ₹1,740.00 (Nov 21, 2025) |
| % from All-Time High | -81.86% | -28.35% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.99% | 0.98% |
| Quarterly Earnings Growth | -1.00% | 1.12% |
| Financial Health | ||
| Profit Margin (TTM) | -2.42% | -0.15% |
| Operating Margin (TTM) | -28.88% | -0.16% |
| Return on Equity (TTM) | -0.21% | -0.25% |
| Debt to Equity (MRQ) | 94.48 | 56.90 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹18.24 | ₹103.04 |
| Cash per Share (MRQ) | ₹2.07 | ₹1.87 |
| Operating Cash Flow (TTM) | ₹87.48M | ₹-1,007,999,000 |
| Levered Free Cash Flow (TTM) | ₹-166,388,000 | ₹-563,984,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.07% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs Zota Health Care Limited
| Metric | BIBCL (Apr 26, 2026) | ZOTA (Apr 22, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.59 | -62.53 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -0.08 | -0.59 |
| Price to Sales (TTM) | 9.97 | 8.34 |
| Price to Book (MRQ) | 0.97 | 12.61 |
| Market Capitalization | ||
| Market Capitalization | ₹762.99M | ₹39.41B |
| Enterprise Value | ₹1.42B | ₹45.66B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 18.52 | 9.66 |
| Enterprise to EBITDA | -7.13 | -126.59 |
| Risk & Other Metrics | ||
| Beta | 0.34 | 0.36 |
| Book Value per Share (MRQ) | ₹18.24 | ₹103.04 |
Financial Statements Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs Zota Health Care Limited
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | BIBCL (2023) | ZOTA (2025) |
|---|---|---|
| Revenue/Sales | 446.09M | 2.93B |
| Cost of Goods Sold | 422.08M | 1.44B |
| COGS % of Revenue | 94.6% | 49.0% |
| Gross Profit | 24.01M | 1.49B |
| Gross Margin | 5.4% | 51.0% |
| Research & Development | 0 | N/A |
| Operating Income (EBIT) | -160.07M | -480.90M |
| Operating Margin | -35.9% | -16.4% |
| EBITDA | -154.93M | -42.20M |
| EBITDA Margin | -34.7% | -1.4% |
| Pre-Tax Income | -222.68M | -576.44M |
| Pre-Tax Income % of Revenue | -49.9% | -19.7% |
| Income Tax | -56.29M | -9.06M |
| Income Tax % of Revenue | -12.6% | -0.3% |
| Net Income (Profit) | -166.39M | -567.39M |
| Profit Margin | -37.3% | -19.4% |
Balance Sheet & Liquidity Metrics
| Metric | BIBCL (2023) | ZOTA (2025) |
|---|---|---|
| Cash & Equivalents | 12.86M | 21.32M |
| Total Current Assets | 358.03M | 1.84B |
| Total Current Assets % of Revenue | 80.3% | 62.9% |
| Total Current Liabilities | 940.42M | 1.01B |
| Total Current Liabilities % of Revenue | 210.8% | 34.3% |
| Long-Term Debt | N/A | 1.08B |
| Long-Term Debt % of Revenue | 0.0% | 36.7% |
| Total Shareholders Equity | 882.14M | 2.27B |
| Retained Earnings | -662.11M | -191.89M |
| Retained Earnings % of Revenue | -148.4% | -6.5% |
| Property, Plant & Equipment | 72.02M | 65.25M |
Cash Flow Statement Comparison
| Metric | BIBCL (2023) | ZOTA (2025) |
|---|---|---|
| Operating Cash Flow | 87.48M | -1.01B |
| Operating Cash Flow % of Revenue | 19.6% | -34.4% |
| Capital Expenditures | 0 | -459.67M |
| Free Cash Flow | 108.92M | -959.42M |
| FCF Margin | 24.4% | -32.7% |
| Debt Repayment | N/A | -140.67M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIBCL | ZOTA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 43.18M | 30.33M |
| Float Shares | 17.58M | 15.02M |
| % Held by Insiders | 59.25% | 0.00% |
| % Held by Institutions | 0.00% | 1.16% |
| % Held by Public | 40.75% | 98.84% |
Dividend Analysis & Yield Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs Zota Health Care Limited
| Metric | BIBCL | ZOTA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.07% |
| 3-Year Avg Annual Dividend | N/A | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.16% |
| 3-Year Total Dividends | N/A | ₹3.00 |
| Ex-Dividend Date | N/A | Sep 22, 2025 |